Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Sudha T., Yalcin M., Lin H., Elmetwally A. M., Nazeer T., Arumugam T., ...Daha Fazla

CANCER LETTERS, cilt.350, ss.25-33, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 350
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.canlet.2014.04.016
  • Dergi Adı: CANCER LETTERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.25-33
  • Anahtar Kelimeler: Low molecular weight heparin, Pancreatic cancer, Non-anticoagulant heparin, Anti-cancer, Tumor suppressor, Tumor survival, FACTOR PATHWAY INHIBITOR, TUMOR-GROWTH, P-SELECTIN, SURVIVAL, ANGIOGENESIS, METASTASIS, ENOXAPARIN, RESISTANCE, THROMBOSIS, INVASION
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.